BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21622973)

  • 1. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.
    Fischer A; Yang SJ; Bayer AS; Vaezzadeh AR; Herzig S; Stenz L; Girard M; Sakoulas G; Scherl A; Yeaman MR; Proctor RA; Schrenzel J; François P
    J Antimicrob Chemother; 2011 Aug; 66(8):1696-711. PubMed ID: 21622973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.
    Bertsche U; Yang SJ; Kuehner D; Wanner S; Mishra NN; Roth T; Nega M; Schneider A; Mayer C; Grau T; Bayer AS; Weidenmaier C
    PLoS One; 2013; 8(6):e67398. PubMed ID: 23785522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.
    Mishra NN; Yang SJ; Chen L; Muller C; Saleh-Mghir A; Kuhn S; Peschel A; Yeaman MR; Nast CC; Kreiswirth BN; Crémieux AC; Bayer AS
    PLoS One; 2013; 8(8):e71151. PubMed ID: 23990934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.
    Kang KM; Mishra NN; Park KT; Lee GY; Park YH; Bayer AS; Yang SJ
    J Microbiol; 2017 Feb; 55(2):153-159. PubMed ID: 28120188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.
    Bertsche U; Weidenmaier C; Kuehner D; Yang SJ; Baur S; Wanner S; Francois P; Schrenzel J; Yeaman MR; Bayer AS
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3922-8. PubMed ID: 21606222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibacterial mechanism of daptomycin antibiotic against Staphylococcus aureus based on a quantitative bacterial proteome analysis.
    Ma W; Zhang D; Li G; Liu J; He G; Zhang P; Yang L; Zhu H; Xu N; Liang S
    J Proteomics; 2017 Jan; 150():242-251. PubMed ID: 27693894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus.
    Yang SJ; Kreiswirth BN; Sakoulas G; Yeaman MR; Xiong YQ; Sawa A; Bayer AS
    J Infect Dis; 2009 Dec; 200(12):1916-20. PubMed ID: 19919306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.
    Ma Z; Lasek-Nesselquist E; Lu J; Schneider R; Shah R; Oliva G; Pata J; McDonough K; Pai MP; Rose WE; Sakoulas G; Malik M
    PLoS One; 2018; 13(6):e0198366. PubMed ID: 29879195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
    Yang SJ; Nast CC; Mishra NN; Yeaman MR; Fey PD; Bayer AS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3079-85. PubMed ID: 20498310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant
    Taglialegna A; Varela MC; Rosato RR; Rosato AE
    mSphere; 2019 Feb; 4(1):. PubMed ID: 30760612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus.
    Cafiso V; Bertuccio T; Purrello S; Campanile F; Mammina C; Sartor A; Raglio A; Stefani S
    Int J Antimicrob Agents; 2014 Jan; 43(1):26-31. PubMed ID: 24183798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons.
    Mishra NN; Bayer AS; Weidenmaier C; Grau T; Wanner S; Stefani S; Cafiso V; Bertuccio T; Yeaman MR; Nast CC; Yang SJ
    PLoS One; 2014; 9(9):e107426. PubMed ID: 25226591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ; Hady WA; Bayer AS; Chen L; Kreiswirth BN; Yang SJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.
    Mehta S; Cuirolo AX; Plata KB; Riosa S; Silverman JA; Rubio A; Rosato RR; Rosato AE
    Antimicrob Agents Chemother; 2012 Jan; 56(1):92-102. PubMed ID: 21986832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.
    Jiang JH; Dexter C; Cameron DR; Monk IR; Baines SL; Abbott IJ; Spelman DW; Kostoulias X; Nethercott C; Howden BP; Peleg AY
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
    Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
    Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus:
    Mishra NN; Lew C; Abdelhady W; Lapitan CK; Proctor RA; Rose WE; Bayer AS
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164921. PubMed ID: 34694870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential daptomycin resistance development in Staphylococcus aureus strains with active and mutated gra regulatory systems.
    Müller A; Grein F; Otto A; Gries K; Orlov D; Zarubaev V; Girard M; Sher X; Shamova O; Roemer T; François P; Becher D; Schneider T; Sahl HG
    Int J Med Microbiol; 2018 Apr; 308(3):335-348. PubMed ID: 29429584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").
    Yang SJ; Xiong YQ; Boyle-Vavra S; Daum R; Jones T; Bayer AS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3161-9. PubMed ID: 20547804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.